Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study ; volume:12 ; number:1 ; day:13 ; month:1 ; year:2011 ; pages:1-6 ; date:12.2011
BMC musculoskeletal disorders ; 12, Heft 1 (13.1.2011), 1-6, 12.2011
- Creator
-
van den Bemt, Bart JF
- Contributor
-
den Broeder, Alfons A.
Wolbink, GJ
Hekster, Yechiel A.
van Riel, Piet LCM
Benraad, Bart
van den Hoogen, Frank HJ
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-12-12
- URN
-
urn:nbn:de:1111-2016043018296
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- van den Bemt, Bart JF
- den Broeder, Alfons A.
- Wolbink, GJ
- Hekster, Yechiel A.
- van Riel, Piet LCM
- Benraad, Bart
- van den Hoogen, Frank HJ
- SpringerLink (Online service)
Other Objects (12)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know